According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development. So we are in fairly close agreement. That
Continue reading QIDP Drug Update – Part 2: Categories of Interest → Like this: Like Loading...
Posted in QIDP Antibiotics, Recent Literature, The News, The Viewpoint |
Tagged antibiotic blog, AstraZeneca, Avycaz, aztreonam, Brilacidin, bronchiectasis, ceftaroline, ceftaroline/avibactam, ceftazidime, Cellceutix, chitin synthase inhibitor, CTAZ/AVI, Entasis, Gepotidacin, GSK, Harald Reinhart, lefamulin, LptD inhibitor, N. gonorrhoeae, Nabriva, NDM, New Delhi metallobetalactamase, NikZ, non-tuberculous mycobacteria, NTM, Peptidomimetic, piperacillin/tazobactam, pleuromutilin, POL-7080, Polyphor, QIDP, TOBI, tobramycin inhaler, VABP treatment, Valley Fever Solutions, VAPB prophylaxis, Zoliflodacin, Zosyn |
It is time for a new look at the field of QIDP drugs. Today we are providing an updated searchable database which now has 57 entries. (Status: 10/18/16) Despite best efforts to provide accurate information, errors may have crept in. Please let us
Continue reading QIDP Drug Update – Part 1: An Updated Who Is Who → Like this: Like Loading...
Posted in QIDP Antibiotics, The News |
Tagged Achaogen, Actelion, AeroVanc, Allergan, antibiotic blog, antibiotic development, Aradigm, Avycaz, Basilea, Baxdela, Bayer, Brilacidin, Cadazolid, Cardeas, Ceftazidime/avibactam, Cellceutix, Cempra, Cidara, Citius, CorMedix, Dalvance, daptomycin, Debiopharm Pharmaceuticals, delafloxacin, Destiny, Entasis, eravacycline, FDA, fosfomycin, Fusidic Acid, GSK, Harald Reinhart, iclaprim, Innocoll, Insmed, Ixodes, Matinas, Meiji Seika Pharma, Melinta, Merck, MGB Biopharma, Microbion, Morphochem, Motif Bio, Nabriva, Nemonoxacin, neutrolin, omadacycline, oritavancin, Paratek, plazomicin, Polyphor, QIDP, QIDP list of antibiotics, Raptor, RedHill Biopharma, Savara, Scynexis, Sivextro, Solithera, solithromycin, SPA, special protocol assessmentn, Summit, Surotomycin, Symbiomix, TaiGen, tedizolid, Tetraphase, The Medicines Company, Valley Fever Solutions, Viamet, Vical, Wockhardt, Zavante, Zinforo |
In the last decade (2000-2010), we saw the number of new antibiotic approvals drop successively each year; FDA changed the rules of the approval process without providing public guidance; many antibiotic companies fled the therapeutic area; investments were redirected to
Continue reading The 10 x ’20 Goal – Are We On Track? → Like this: Like Loading...
Posted in The News, The Viewpoint |
Tagged Allphase Pharma Consulting, antibiotic blog, antibiotic pipeline, AstraZeneca, Avycaz, aztreonam/avibactam, Basilea, Bayer, bedaquiline, ceftaroline, Ceftazidime/avibactam, ceftolozane/tazobactam, dalbavancin, Dalvance, defensin, delafloxacin, Dificid, eravacycline, FabI inhibitor, fidoxamicin, Harald Reinhart, MDR drugs, Merck, omadacycline, Orbactiv, oritavancin, Paratek, Pfizer, POL7080, Polyphor, Roche, Shionogi, Sirturo, Sivextro, tedizolid, televancin, Tetraphase, Vibativ, Zerbaxa, Zinforo |
VABP is clearly the main indication to be pursued by a drug like POL7080. Here is the question: How to conduct a study demonstrating efficacy for a drug which only has a single-organism spectrum? Which is actually no spectrum at all. Existing
Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 3) → Like this: Like Loading...
Posted in QIDP Antibiotics, The Viewpoint |
Tagged Allphase Pharma Consulting, antibiotic blog, cefepime, ceftazidime, Doribax, doripenem, FDA, feasibility, Fortaz, Harald Reinhart, malaria, meropenem, Merrem, MTB, pipercillin/tazobactam, POL7080, Polyphor, Roche, VABP, VABP Guidance |
Roche’s current Phase 2 program is strangely ambiguous. RG-7929 has not made it into www.clinicaltrials.gov yet, only POL7080 is listed. An uncontrolled open label study in “patients with non-CF acute exacerbation of bronchiectasis due to P. aeruginosa requiring IV treatment”
Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 2) → Like this: Like Loading...
Posted in QIDP Antibiotics, The News, The Viewpoint |
Tagged antibiotic blog, bacteremia, bronchiectasis, Cubicin, Cubist, daptomycin, Doribax, doripenem, endocarditis, FDA, Francis Tally, malignant otitis externa, MRSA, P. aeruginosa, POL7080, Polyphor, RG-7929, Roche, sepsis, tigecycline, Tygacil, UTI, VABP, VAP, VAP bundle |